17 results about "Isoliquiritigenin" patented technology

The invention provides a cough-relieving and phlegm-eliminating composition and a preparation method thereof. The cough-relieving and phlegm-eliminating composition is prepared from the following raw materials: anhydrous morphine, anhydrous codeine phosphate, apigenin, liquiritin, isoliquiritin, liquiritigenin, isoliquiritigenin, glycyrrhizic acid, trans-anethole, camphor and sodium benzoate. The composition further comprises a luffa stem extract, an atractylodes lancea rhizome extract and a radix ranunculi ternati bark extract. The cough-relieving and phlegm-eliminating composition provided by the invention has the advantages of few impurities, clear and remarkable drug effect and small side effect. Under the action of the core antitussive drug, three plant extracts of luffa stem, Atractylodes lancea and Ranunculus ternatus Thunb. Are creatively added, so that the phlegm eliminating capacity and the overall antitussive effect of the whole formula are remarkably enhanced. The cough-relieving and phlegm-eliminating composition disclosed by the invention realizes the synergistic interaction of '1 + 1 + 1gt, 3' on the core indexes of inhibiting the cough frequency, prolonging the cough latency period, promoting sputum excretion and the like, and realizes the cough-relieving and phlegm-eliminating effects of treating both symptoms and root causes through the multi-target-point and multi-mechanism synergistic effect.

A small molecule composition, comprising licochalcone A, licochalcone C, licochalcone D, licochalcone E, echinatin, isoliquiritigenin, formononetin, liquiritigenin, licoflavone C, glabrol, licoisoflavone A and licoisoflavone B, and the use thereof in preparing anticancer or antitumor drugs, anti-ferroptosis drugs, or drugs for sensitization of anticancer or antitumor drugs. The small molecule composition can also be used in combination with other antitumor drugs.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a method for simultaneously extracting and purifying glabridin, glycyrrhizic acid and isoliquiritigenin. The method comprises the following steps: (1) adding ethanol into glycyrrhiza glabra, and extracting to obtain an extracting solution; (2) extracting the extracting solution with ethyl acetate to obtain an organic phase and a water phase; and (3) purifying the organic phase by using a rapid preparative liquid chromatograph, carrying out gradient elution by using 30%-70% of ethyl acetate-cyclohexane as a mobile phase, and collecting the eluent, thereby obtaining the glabridin. (4) carrying out acidification and centrifugal precipitation on the water phase to obtain a glycyrrhizic acid crude product and a supernatant, adding absolute ethyl alcohol into the glycyrrhizic acid crude product, and carrying out ultrasonic extraction and centrifugation to obtain a glycyrrhizic acid ethanol solution; and (5) extracting and purifying the supernate to obtain the isoliquiritigenin.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a method for simultaneously extracting and purifying glabridin, glycyrrhizic acid and isoliquiritigenin by a column chromatography extraction method. The method comprises the following steps: adding an ethanol solution into glycyrrhiza glabra, extracting by adopting a column chromatography extraction method, extracting an extracting solution by using dichloroethane, enabling an organic phase to pass through a silica gel column, and crystallizing an eluent to obtain glabridin. Acidifying and centrifuging the extracted water phase, and dissolving the precipitate with acetone to obtain glycyrrhizic acid; and extracting and purifying the filtrate to obtain the isoliquiritigenin. The invention provides a simple and efficient new extraction technology which is low in energy consumption, small in solvent dosage and high in extraction rate compared with traditional ultrasonic extraction and the like, and aims to extract glycyrrhizic acid and glabridin in glycyrrhiza glabra at the same time, separate glycyrrhizic acid and glabridin, separate isoliquiritigenin from the remaining part through simple conversion, and improve the purity of glycyrrhizic acid and glabridin in glycyrrhiza glabra. The comprehensive development and utilization of the glycyrrhiza glabra are achieved.

The invention discloses application of isoliquiritigenin in preparation of a medicine for treating 5-FU induced cardiotoxicity, and belongs to the technical field of biomedicine.The medicine comprises the isoliquiritigenin, and the isoliquiritigenin improves 5-FU induced oxidative stress and apoptosis by regulating an AhR-CYP1A1 pathway, so that the 5-FU induced cardiotoxicity is improved; the invention systematically reveals the action mechanism of the isoliquiritigenin for improving the 5-FU-induced cardiotoxicity by inhibiting an AhR-CYP1A1 signal channel for the first time from the animal overall level and the cell molecule level to mechanism analysis, and proves the application value of the isoliquiritigenin in preparation of the medicine for treating the 5-FU-induced cardiotoxicity; based on complete analysis of the mechanism, the invention provides a brand new active ingredient and a technical scheme for preparing the medicine for resisting 5-FU cardiotoxicity, lays a theoretical and experimental foundation for research and development of the medicine for relieving the side effect of 5-FU chemotherapy, and has an important medicine development value.

The invention discloses a method for screening anti-inflammatory heart protection active components of Siji decoction. The method comprises the following steps: 1, finding eicosanoic acid related to the drug effect of the Siji decoction and measuring the content of eicosanoic acid; 2, identification of components absorbed into blood by the Siji decoction and determination of relative peak intensity; and 3, analyzing the correlation between the content of the eicosanoic acid metabolite related to the drug effect of the Siji decoction and the relative peak intensity of the component absorbed into blood by the Siji decoction, and screening the anti-inflammatory heart protection active component of the Siji decoction. The method comprises the following steps: by taking an eicosanoic acid metabolic profile as a drug effect target, constructing a correlation model of quantitative information of eicosanoic acid metabolites in a rat with heart failure at different time points and blood-entering component intensities of Siji decoction at different time points; through screening, it is determined that the four components of songorine, neoline, talasamine and isoliquiritigenin have the definite anti-inflammatory heart protection effect, and the method is accurate and efficient.

The application discloses a kind of based on isoliquiritigenin biological base temperature-resistant antibacterial foam cotton material and preparation method and application thereof, the foam cotton material is obtained by foaming based on the main chain type benzoxazine resin of isoliquiritigenin biological base, with maleic anhydride, foaming agent master batch, the main chain type benzoxazine resin of based on isoliquiritigenin biological base molecular formula as shown below.The application is prepared with the main chain type benzoxazine resin of isoliquiritigenin biological base as organism to obtain the benzoxazine foam with temperature-resistant antibacterial property of body.The foam cotton material of the application has the following advantages: based on the molecular structure of isoliquiritigenin, product has excellent antibacterial property;High crosslinking density benzoxazine gives product excellent temperature resistance;The product thermal conductivity is as low as 0.033W / (m·K), and the product has wide application in medical equipment, electronic equipment, new energy automobile and other fields.

The present invention relates to a composition of paeoniflorin and isoliquiritigenin and application thereof. The composition according to the present invention is rich in raw materials, and has the effects of anti-inflammation, antioxidant, inhibiting collagen deposition, etc., and can be effectively used to treat diffuse interstitial pulmonary fibrosis with high economic and social benefits.

This invention belongs to the field of biomedical technology, specifically relating to an isoliquiritigenin composition for improving depression and its preparation method. The isoliquiritigenin composition for improving depression comprises the following raw materials in parts by weight: 22-40 parts isoliquiritigenin, 10-17 parts N-acetyl-D-glucosamine, and 15-20 parts β-lapaquinone. Isoliquiritigenin, N-acetyl-D-glucosamine, and β-lapaquinone constitute a multi-target synergistic isoliquiritigenin composition for improving depression. Experimental results show that by taking the isoliquiritigenin composition prepared according to this invention, it can systematically exert its effects and comprehensively improve the pathological state of depression, showing broad application prospects.

The invention discloses an application of isoliquiritigenin and / or glabridin in preparation of a medicine for treating acanthamoeba infection. The research finds that the isoliquiritigenin and the glabridin are adopted to treat the acanthamoeba trophoblast cells, proliferation of the acanthamoeba trophoblast cells can be remarkably inhibited, toxicity to host cells is small, and the inhibition effect of the isoliquiritigenin and the glabridin on the acanthamoeba is more remarkable when the isoliquiritigenin and the glabridin are matched. Therefore, the isoliquiritigenin and / or glabridin can be used for preparing medicines or preparations for preventing and / or treating diseases caused by acanthamoeba infection, removing acanthamoeba cells or inhibiting acanthamoeba cell proliferation.

The invention relates to the technical field of medicines, in particular to application of isoliquiritin in preparation of medicines for preventing and treating mustard gas nerve injury. The invention also provides an application of isoliquiritin in preparation of neuroprotective drugs. The isoliquiritin exerts effective neuroprotective activity on mustard gas injury, can remarkably improve the situation that the survival rate of PC12 cells is reduced due to mustard gas, remarkably inhibits LDH outflow and ROS rising of the cells, and relieves cell DNA injury caused by mustard gas. At the animal level, mouse brain tissue neuronal degeneration and nissl body reduction caused by mustard gas are improved, and the spontaneous activity condition of mouse brain tissue neuronal degeneration and nissl body reduction are improved. The invention provides a new reference way for treating mustard gas nerve injury, and the isoliquiritin has a prospect of preparing a neuroprotective agent aiming at mustard gas.

The invention relates to an application of isoliquiritigenin in preparation of chronic wound medicines or medical instruments. The invention also provides a nano drug delivery system which is covalent organic framework nano particles (ISL (at) bCOF) loaded with isoliquiritigenin. The COF carrier is connected with an ISL molecule through a boron-oxygen bond, and a'gating 'system sensitive to a wound surface high-glucose microenvironment is constructed. In a normal physiological environment, the boron-oxygen bond is stable, and the drug release is slow; when in a high-glucose environment of a chronic wound surface, the boric acid ester bond is broken, so that the ISL is quickly and specifically released and acts on macrophages at the wound surface in a targeting manner. Meanwhile, by matching with a high-strength hydrogel microneedle substrate, the prepared microneedle has excellent mechanical strength, can be ensured to be enough to pierce a skin cuticle, has good biocompatibility and high permeability, and is convenient to package and deliver the nano drug delivery system.

The invention discloses a hematoxyloxymethyltransferase CsOMT80 mutant and an application of the hematoxyloxymethyltransferase CsOMT80 mutant in synthesis of chalcone compounds. Through structural biological modeling and functional site analysis, on the basis of hematoxylon multi-omics data and identification, an oxygen methyltransferase coding gene CsOMT80 closely related to methoxychalcone synthesis is obtained, structural prediction and molecular docking are performed on an amino acid sequence of the oxygen methyltransferase coding gene CsOMT80, and key sites influencing substrate binding and catalytic efficiency are screened out. On the basis, amino acid replacement is carried out on a target site by adopting a site-directed mutagenesis strategy, and a plurality of mutants are constructed and obtained. Functional verification finds that the mutant CsOMT80G112R shows remarkably enhanced catalytic efficiency when a catalytic reaction is carried out by taking isoliquiritigenin as a substrate, and the enzymatic activity of the mutant CsOMT80G112R is 1278 times that of a wild type and is superior to that of reported O-methyltransferase (ChOMT) from alfalfa.

The application provides a drug-loaded liposome loaded with isoglycyrrhizin, a preparation method and application thereof, and relates to the technical field of medicines.The drug-loaded liposome is prepared from raw materials containing lecithin 20-50 parts by weight, glycyrrhetic acid 6-15 parts by weight and isoglycyrrhizin 2-10 parts by weight, and can be used as a new drug for treating androgenetic alopecia.

The invention discloses application of isoliquiritigenin in preparation of a product for treating primary hypertension, and belongs to the technical field of medicines. Experimental verification finds that the isoliquiritigenin improves primary hypertension vascular remodeling by reducing proliferation and migration capabilities of medial vascular smooth muscle cells and promoting the vascular smooth muscle cells to be converted from a synthetic type to a contractile type at the same time. The invention provides a new medicine for treating primary hypertension, and meanwhile, the new application of the isoliquiritigenin provides a new way for comprehensively developing medicinal resources of the isoliquiritigenin.

The invention belongs to the technical field of biology, and discloses application of isoliquiritigenin in preparation of a product for preventing and / or treating fish infected with a siniperca chuatsi and frog iridovirus (MRV), the EC50 of the isoliquiritigenin is 3.08 mu M, and the isoliquiritigenin has a remarkable in-vivo and in-vitro anti-MRV effect, so that the treatment administration effect is the best, the premixing administration is the second time, and the effect of preventing and / or treating the fish infected with the siniperca chuatsi and frog iridovirus is achieved. The result shows that the isoliquiritigenin possibly has a direct damage effect on MRV virus particles and inhibits MRV virus proliferation; besides, excessive inflammation and cell apoptosis caused by MRV infection can cause fish tissue damage and can promote virus proliferation and escape, and isoliquiritigenin can relieve tissue damage caused by MRV virus, inhibit virus proliferation and play a comprehensive antiviral role through anti-inflammatory and anti-apoptosis effects; meanwhile, the invention also provides a medicine containing isoliquiritigenin, a fish feed and a fish feed additive.